Abstract
Seventy consecutive patients with refractory or relapsed Hodgkin’s disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytarabine and cyclophosphamide (BEAC). The 5-year Kaplan–Meier event-free survival (EFS) for the entire cohort was 32% (95% confidence interval; 18–45%) with a median follow-up of 3.6 years (range 7 months–7.6 years). The most significant predictor of improved survival was the presence of minimal disease (defined as all areas ⩽2 cm) at the time of transplant: the 5 years EFS was 46 vs 10% for patients with bulky disease (P = 0.0002). Other independent predictors identified by step-wise regression analysis included the presence of non-refractory disease and the administration of post-transplant involved-field radiotherapy (XRT). Treatment-related mortality occurred in 13 of 70 patients: nine patients (13%) died within the first 100 days, mainly from cardiopulmonary toxicity. However, only one of 24 patients (4%) transplanted during the last 4.5 years died from early treatment-related complications. While high-dose therapy followed by autotransplantation led to long-term EFS of 50% for patients with favorable prognostic factors, a substantial proportion of patients relapsed, indicating that new therapeutic strategies are needed.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lancet, J., Rapoport, A., Brasacchio, R. et al. Autotransplantation for relapsed or refractory Hodgkin’s disease: long-term follow-up and analysis of prognostic factors. Bone Marrow Transplant 22, 265–271 (1998). https://doi.org/10.1038/sj.bmt.1701325
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1701325
Keywords
This article is cited by
-
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma
Bone Marrow Transplantation (2022)
-
Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
BMC Cancer (2020)
-
Post-autologous transplant maintenance therapies in lymphoma: current state and future directions
Bone Marrow Transplantation (2018)
-
The relationship between absolute lymphocyte count with PFS in patients with Hodgkin's lymphoma undergoing autologous hematopoietic cell transplant
Bone Marrow Transplantation (2008)
-
Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: A Prospective Australasian Leukaemia and Lymphoma Group Study
Bone Marrow Transplantation (2005)